Upcoming Event

What are the considerations of treating CAD beyond ASA? Is it time for a new gold standard?

Monday, May 11, 2020 12:15 p.m. EST

Approximate running time: 1 hour

Featuring

Michael Heffernan , MD, PhD, FRCPC, FACC

Language: English

Learning Objectives

  • Screen and identify high-risk CAD patients and evaluate the need for additional anti-thrombotic treatment
  • Effectively counsel patients in understanding the need for additional anti-thrombotic treatment
  • Discuss the benefits and risks of current antithrombotic therapies in patients with CAD"

Therapeutic area: Cardiology/Vascular Disease